Highlights from WCLC 2026
1 in 4 UK Royal Cancer Stories Contained Alarming Misinformation, Study Finds
Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?
Chiaojung Jillian Tsai: The CURB2 Trial and the Next Question in Oligoprogressive NSCLC
Yüksel Ürün at COGC 2026: Approval Creates Possibility, Access Creates Impact
Santiago Millan and Anjali Srivastava։ WHO’s First-Ever Prequalification EOI for Childhood Cancer Medicines
The CML Evolution: Mastering Modern Algorithms in Chronic Myeloid Leukemia
Cesaltina Lorenzoni: Grateful for National Recognition of Oncology Advancements in Mozambique
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
Our calculators apply published formulas as precisely as we can. Even so, no formula captures every detail of a real patient. Use the result as one input to your own assessment, not the final word.
